Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2000 1
2003 3
2004 3
2005 1
2006 4
2007 3
2008 3
2009 5
2010 5
2011 7
2012 14
2013 13
2014 13
2015 12
2016 7
2017 12
2018 13
2019 10
2020 6
2021 18
2022 4
2024 0

Text availability

Article attribute

Article type

Publication date

Similar articles for PMID: 23948997

128 results

Results by year

Filters applied: . Clear all
Page 1
Randomized phase II study of S-1 dosing schedule for resected colorectal cancer.
Matsuda C, Uemura M, Nakata K, Shingai T, Nishimura J, Hata T, Ikenaga M, Takemasa I, Mizushima T, Kato T, Ikeda M, Ohue M, Murata K, Hasegawa J, Satoh T, Yamamoto H, Sekimoto M, Nezu R, Doki Y, Mori M. Matsuda C, et al. BMC Cancer. 2015 Jun 3;15:452. doi: 10.1186/s12885-015-1476-6. BMC Cancer. 2015. PMID: 26036466 Free PMC article. Clinical Trial.
Four courses versus eight courses of adjuvant S-1 for patients with stage II gastric cancer (JCOG1104 [OPAS-1]): an open-label, phase 3, non-inferiority, randomised trial.
Yoshikawa T, Terashima M, Mizusawa J, Nunobe S, Nishida Y, Yamada T, Kaji M, Fukushima N, Hato S, Choda Y, Yabusaki H, Yoshida K, Ito S, Takeno A, Yasuda T, Kawachi Y, Katayama H, Fukuda H, Boku N, Sano T, Sasako M. Yoshikawa T, et al. Lancet Gastroenterol Hepatol. 2019 Mar;4(3):208-216. doi: 10.1016/S2468-1253(18)30383-2. Epub 2019 Jan 22. Lancet Gastroenterol Hepatol. 2019. PMID: 30679107 Clinical Trial.
Randomized phase II study of daily and alternate-day administration of S-1 for advanced gastric cancer (JFMC43-1003).
Tanaka H, Kanda M, Morita S, Taguri M, Nishikawa K, Shimada M, Muguruma K, Koeda K, Takahashi M, Nakamori M, Konno H, Tsuji A, Hosoya Y, Shirasaka T, Yamamitsu S, Sowa M, Kitajima M, Okajima M, Kobayashi M, Sakamoto J, Saji S, Hirakawa K. Tanaka H, et al. Int J Clin Oncol. 2017 Dec;22(6):1052-1059. doi: 10.1007/s10147-017-1157-3. Epub 2017 Jun 30. Int J Clin Oncol. 2017. PMID: 28667408 Free PMC article. Clinical Trial.
S-1 plus cisplatin versus S-1 alone for first-line treatment of advanced gastric cancer (SPIRITS trial): a phase III trial.
Koizumi W, Narahara H, Hara T, Takagane A, Akiya T, Takagi M, Miyashita K, Nishizaki T, Kobayashi O, Takiyama W, Toh Y, Nagaie T, Takagi S, Yamamura Y, Yanaoka K, Orita H, Takeuchi M. Koizumi W, et al. Lancet Oncol. 2008 Mar;9(3):215-21. doi: 10.1016/S1470-2045(08)70035-4. Epub 2008 Feb 20. Lancet Oncol. 2008. PMID: 18282805 Clinical Trial.
Randomized phase II study of daily and alternate-day administration of S-1 for adjuvant chemotherapy in completely-resected stage I non-small cell lung cancer: results of the Setouchi Lung Cancer Group Study 1301.
Okumura N, Soh J, Suzuki H, Nakata M, Fujiwara T, Nakamura H, Sonobe M, Fujinaga T, Kataoka K, Gemba K, Kataoka M, Hotta K, Yoshioka H, Matsuo K, Sakamoto J, Date H, Toyooka S. Okumura N, et al. BMC Cancer. 2021 May 6;21(1):506. doi: 10.1186/s12885-021-08232-6. BMC Cancer. 2021. PMID: 33957881 Free PMC article. Clinical Trial.
Adherence and feasibility of 2 treatment schedules of S-1 as adjuvant chemotherapy for patients with completely resected advanced lung cancer: a multicenter randomized controlled trial.
Hata Y, Kiribayashi T, Kishi K, Nagashima M, Nakayama T, Ikeda S, Kadokura M, Ozeki Y, Otsuka H, Murakami Y, Takagi K, Iyoda A. Hata Y, et al. BMC Cancer. 2017 Aug 29;17(1):581. doi: 10.1186/s12885-017-3584-y. BMC Cancer. 2017. PMID: 28851314 Free PMC article. Clinical Trial.
128 results